Saturday 17 October 2026
Export IMNM’s income statement to Excel — free account
Immunome, Inc.
IMNM Healthcare Biotechnology
Immunome, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.9 million, down 23.2% from fiscal 2024. In the quarter to June 2026, revenue grew 69.8%, EPS fell 30.0% and free cash flow fell 27.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
16.47
0.93
−5.34%
Follow IMNM
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(93.04%) | (52.09%) | (50.14%) | (64.03%) | |
| (80.08%) | (46.00%) | (46.67%) | (59.03%) | ||
ROIC |
0.00% | 0.00% | (2,490.49%) | (3,322.99%) | |
Return on Tangible Assets |
(85.66%) | (33.69%) | (38.46%) | (48.90%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(2.18) | (2.30) | (1.82) | (1.93) | |
Free Cash Flow |
(191.84) | (200.60) | (205.52) | (219.09) | |
Capital Expenditures |
(6.81) | (9.68) | (9.02) | (10.29) | |
| Other line items | |||||
Cash ROIC |
(35.75%) | (15.58%) | (17.55%) | (20.96%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.83 | 0.90 | 0.87 | 0.82 | |
Depreciation/Fixed assets |
(0.05) | 0.01 | 0.06 | 0.12 | |
Capex/Depreciation |
11.33 | (83.49) | (9.39) | (4.76) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(2.10) | (2.19) | (1.74) | (1.84) | |
Capex per Share |
(0.08) | (0.11) | (0.08) | (0.09) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates